Biologically, BTK inhibition interferes, within the tumor microenvironment, with different pathways required for CLL cell survival and proliferation such as the B-cell receptor (BCR) [5, 6], integrins [7] and cytokines/chemokines receptors [8, 9]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.